ArticlePharmacoEconomics - open2023

Cost-Effectiveness Analysis of Siltuximab for Australian Public Investment in the Rare Condition Idiopathic Multicentric Castleman Disease.

Francis Shupo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.